Biotech Values

[DewDiligence]

…MRK is trying to say that even though prior nulls were excluded from RESPOND-2 study, since 25% of patients in the trial had < 1 log reduction in viral load at week 4 while in the lead, they might be considered nulls.

Understood; however, this is a less stringent definition of null responder than the definition used by VRTX (#msg-54315761 bottom), which refers to a prior course of therapy.